246 related articles for article (PubMed ID: 28844082)
1. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
Nazha A; Bejar R
Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
[TBL] [Abstract][Full Text] [Related]
2. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
3. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
4. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
6. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
[TBL] [Abstract][Full Text] [Related]
7. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
8. Implications of molecular genetic diversity in myelodysplastic syndromes.
Bejar R
Curr Opin Hematol; 2017 Mar; 24(2):73-78. PubMed ID: 27875374
[TBL] [Abstract][Full Text] [Related]
9. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
[TBL] [Abstract][Full Text] [Related]
12. Prognostic models in myelodysplastic syndromes.
Bejar R
Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
[TBL] [Abstract][Full Text] [Related]
16. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
18. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
20. [Current diagnosis and treatment for myelodysplastc syndromes].
Hata T
Rinsho Ketsueki; 2017; 58(4):373-380. PubMed ID: 28484169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]